Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...

New study data showed treatment slowed signs of disease progression by 75% after three years, a finding that could have ...

A recent report from Back Bay Life Science Advisors shows a surge in testing of, and investment in, multifunctional ...

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...

Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a ...

Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from ...

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in ...

Recent changes to federal guidance on COVID vaccinations have providers worried about what’s to come. “We have opened a door ...

The deal ends a short run as a publicly traded company for Metsera, which is being sold for more than double its IPO price ...

The company, which is developing a competitor to Cobenfy, aims to become one of rare biotechs to price a large IPO of late.

The collapse in value of many biotechs over the past few years has created an opportunity for specialists like Xoma to “do ...